Condition: Control Condition · Sponsor: Assistance Publique - Hôpitaux de Paris
Liquid chromatography coupled with mass spectrometry (LC-MS/MS) is now the method of choice for steroid hormone analysis, as it enables analyses to be carried out on small-volume samples on a wider range of hormones, with improved specificity compared with immunoassays. Hormone assays currently face a twofold problem: on the one hand, immunoassays are highly dependent on the synthesis of antibody kits manufactured by companies with immunotechnology expertise; on the other hand, these immunoassays may require the use of radioactive products for quantification, generating considerable risks for both staff and environment. There are international recommendations from expert societies (World Anti-Doping Agency, Endocrine society) to develop new, more reliable assay methods, such as LC-MS/MS, and to phase out immuno- and radioassay techniques. However, changing measurement methods requires the development of reference values to maintain and optimize the management of patients. The aim of this project is therefore to establish usual values in a paediatric population, through collaboration between the clinical departments of the APHP and the METOMICS laboratory, which has mastered the technology.
This description comes directly from the study's public registry record.
Eloïse Giabicani, MD, PhD · +33 (0)1 49 28 66 94 · eloise.giabicani@aphp.fr
Marie-Pierre Luton, PhD · +33(0) 1 87 89 26 00 · mariepierre.luton@aphp.fr
Always discuss trial participation with your own doctor first.
| Service d'Endocrinologie Pédiatrique-Explorations Fonctionnelles Hôpital Trousseau | Paris, Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06694415